Abstract: This document relates to oxidative dehydrogenation catalyst materials that include molybdenum, vanadium, oxygen, and iron; oxidative dehydrogenation catalyst materials that include molybdenum, vanadium, oxygen, and aluminum; and oxidative dehydrogenation catalyst materials that include molybdenum, vanadium, oxygen, iron, and aluminum.

Abstract: A method is described for analysis of subsurface data including the use of physics-based modeling and experimental design that allows calculation of probabilities of physical subsurface properties. The method may include calculations of key controlling parameters. The method may include using multiple dimension scaling. The method may be executed by a computer system.

Abstract: This document relates to oxidative dehydrogenation catalyst materials that include molybdenum, vanadium, beryllium, oxygen, and optionally aluminum.

Abstract: Provided in this disclosure are catalyst compositions. The catalyst compositions include an oxidative dehydrogenation catalyst that includes a mixed metal oxide having the empirical formula: Mo1.0V0.12-0.49Te0.05-0.17Nb0.10-0.20AlcOd wherein c is from 0 to 2.0 and d is a number to satisfy the valence of the oxide. The compositions are at least 40 wt. % amorphous as measured by XRD. The disclosure also provides methods of making the compositions.

Abstract: This document relates to oxidative dehydrogenation catalysts that include molybdenum, vanadium, and oxygen.

Abstract: Provided in this disclosure are oxidative dehydrogenation catalysts that include a mixed metal oxide having the empirical formula: Mo1.0V0.12-0.49Te0.05-0.17Nb0.10-0.20Od wherein d is a number to satisfy the valence of the oxide. The oxidative dehydrogenation catalyst is characterized by having XRD diffraction peaks (2? degrees) at 22±0.2, 27±0.2, 28.0±0.2, and 28.3±0.1. The disclosure also provides methods of making the catalysts that include wet ball milling.

Abstract: A subsurface representation may define simulated subsurface configuration of a simulated subsurface region. The simulated subsurface region may include simulated wells, and the simulated subsurface configuration may define simulated correlation between the simulated wells. Subsurface configuration of wells may be compared with the simulated subsurface configuration to generate similarity maps for the wells. Simulated wells may be matched to the wells based on the similarity maps and the arrangement of the wells. Correlation between the wells may be determined based on the simulated correlation between the matched simulated wells.

Abstract: Correlation matrices may be used to simultaneously correlate multiple wells. A correlation matrix may be generated for individual pairs of multiple wells. The values of elements of the correlation matrices may be determined based on matching between segments of the multiple wells and segments of one or more computational stratigraphic models. An N-dimensional space including an axis for individual wells may be generated. Directed walk may be performed within the N-dimensional space to generate paths representing scenarios of correlations for segments of the multiple wells.

Abstract: This document relates to oxidative dehydrogenation catalysts that include molybdenum, vanadium, and oxygen.

Abstract: Disclosed are compositions containing a therapeutically effective amount of free recombinant or synthetic lubricin, a lubricin-supplemented preserved AM, or a lubricin-supplemented non-AM substrate for promoting tissue reconstruction and wound healing in a subject and the methods of using thereof. Lubricin-supplemented preserved amniotic membranes and lubricin-supplemented non-AM substrates, and methods of preparing thereof are also described.

Abstract: Oxidative dehydrogenation catalysts including mixed oxides of Mo, V, Nb, Te, and optionally a promoter may be dissolved in aqueous solutions of oxalic acid. This permits the removal of catalyst and catalyst residues from reactors for the oxidative dehydrogenation of paraffins and particularly ethane.

Abstract: A novel quantum-based computational process for drug discovery and design was used to identify potential novel liver-stage anti-malarial therapeutic molecules. The approach combined the latest big-data advances in high-throughput bioassay development with fundamental scientific knowledge to generate new pharmaceutical leads. Several molecules with no previous association with anti-parasitical activity were identified. These molecules and there use in prevention and/or treatment of Plasmodium infections are provided.

Abstract: A method is described for estimating hydrocarbon reservoir attributes including obtaining a geophysical dataset and a geological dataset; obtaining a parameter model, the parameter model having been conditioned by training an initial parameter model using training data, wherein the geological data includes well data and the training data includes the well data; picking a surface in the geophysical dataset; assigning stratigraphic meaning to the at least one surface based on the geological dataset; identifying at least one region of interest on the at least one surface; generating statistical seismic attributes for the at least one region; identifying critical attributes among the statistical seismic attributes by applying the parameter model to generate response variable maps for the at least one region; and generating uncertainty maps for each of the critical attributes and for the response variables. The method may be executed by a computer system.

Abstract: Mixed metal oxide catalysts having an amorphous content of not less than 40 wt. % are prepared by calcining the catalyst precursor fully or partially enclosed by a porous material having a melting temperature greater than 600° C. in an inert container including heating the catalyst precursor at a rate from 0.5 to 10° C. per minute from room temperature to a temperature from 370° C. to 540° C. under a stream of pre heated gas chosen from steam and inert gas and mixtures thereof at a pressure of greater than or equal to 1 psig having a temperature from 300° C. to 540° C. and holding the catalyst precursor at that temperature for at least 2 hours and cooling the catalyst precursor to room temperature.

Abstract: Oxidative dehydrogenation catalysts comprising MoVNbTeO having improved consistency of composition and a 25% conversion of ethylene at less than 420° C. and a selectivity to ethylene above 95% are prepared by treating the catalyst precursor with H2O2 in an amount equivalent to 0.30-2.8 mL H2O2 of a 30% solution per gram of catalyst precursor prior to calcining.

Abstract: A subsurface representation may define simulated subsurface configuration of a simulated subsurface region. The simulated subsurface region may include simulated wells, and the simulated subsurface configuration may define simulated correlation between the simulated wells. Subsurface configuration of wells may be compared with the simulated subsurface configuration to generate similarity maps for the wells. Simulated wells may be matched to the wells based on the similarity maps and the arrangement of the wells. Correlation between the wells may be determined based on the simulated correlation between the matched simulated wells.

Abstract: Oxidative dehydrogenation catalysts for converting lower paraffins to alkenes such as ethane to ethylene when prepared as an agglomeration, for example extruded with supports chosen from slurries of TiO2, ZrO2 Al2O3, AlO(OH) and mixtures thereof have a lower temperature at which 25% conversion is obtained.

Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.

Abstract: Disclosed herein are new salts and polymorphs of cethromycin for the treatment of diseases due to infection by bacteria and certain protozoans, including, for example, malaria, Babesosis, Toxoplasmosis, diarrheal disease, respiratory disease, sexually transmitted bacterial infections, and some bioterror bacteria, including, for example, plague, tularemia and post-inhalation anthrax. Also disclosed herein are new salts and polymorphs of cethromycin for the treatment of inflammatory diseases, including, for example, pelvic inflammatory disease, and peptic ulcer disease.

Abstract: Oxidative dehydrogenation catalysts for converting lower paraffins to alkenes such as ethane to ethylene when prepared as an agglomeration, for example extruded with supports comprising slurries of Nb2O5.